1511 GMT - Novo Nordisk first-quarter earnings could miss expectations on lower-than-expected prescriptions of Ozempic and Wegovy as well as some price declines, Bank of America Securities analysts write. Growth will also be hit by tough comparables, currency impacts and possibly higher costs, the bank says. "We expect sales guide to be lowered from 16-24% at constant exchange rates to 14%-22%, with our forecasts at the bottom of the new range." BofA assumes limited Ozempic/Wegovy inflection in the second quarter, while a key unknown is if whether a second-half inflection in prescriptions happens against tougher comparables. The bank lowers its price objective to 910 Danish kroner from 1,075 kroner and keeps a buy rating. Shares trade at 475.00 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 28, 2025 11:11 ET (15:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。